ArticleCureus2025
Interstitial Brachytherapy for Early Oral Cavity Squamous Cell Carcinoma: Long-Term Treatment Outcomes From a Single Tertiary Oncology Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/objective This study aimed to evaluate the long-term efficacy of interstitial brachytherapy for the treatment of early oral cavity squamous cell carcinoma (OCSCC). Materials and methods This retrospective review included consecutive patients with early OCSCC (cT1-2N0M0) who underwent primary radiotherapy exclusively by interstitial brachytherapy between January 2000 and December 2020. The primary outcome was local recurrence-free survival (LRFS); secondary outcomes included regional recurrence-free survival (RRFS), disease-free survival (DFS), disease-specific survival (DSS), overall survival (OS), and treatment-related complications. Incidence of late treatment-related complications is reported. Results Thirty-eight patients with early OCSCC underwent interstitial brachytherapy during the study period, of which 20 (52.6%) underwent high dose rate (HDR) brachytherapy with a median dose of 55 Gy and 18 (47.4%) underwent low dose rate (LDR) brachytherapy with a median dose of 66.5 Gy. Elective neck dissection was performed in 33 (86.8%) patients. At a median follow-up time of 11.8 years, the three-year and five-year LRFS were 86.1% and 76.6%, respectively. RRFS was 80.2% at three years and 77.1% at five years; DFS was 73% at three years and 62.2% at five years; DSS was 88.6% at three years and at five years; OS was 78.4% at three years and 75.7% at five years. Local recurrence occurred in 10 (26.3%) patients, with six (60%) salvaged by surgery. Regional recurrence occurred in eight (21.1%) patients, and three (37.5%) were salvaged by neck dissection. Treatment-related complications included persistent tongue ulcer in three (7.9%) patients and osteoradionecrosis of the jaw in four (10.5%) patients. Conclusion Interstitial brachytherapy for early OCSCC yielded acceptable long-term local control and safety data. While radical surgery continues to be the standard of care for OCSCC, interstitial brachytherapy remains an effective and safe alternative for selected patients with early-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.